Trefoil Therapeutics Announces Positive TTHX1114 Phase 2 Study Data Showing Corneal Regeneration and Vision Recovery Following Descemet Stripping Only (DSO) Surgery
CHICAGO--(BUSINESS WIRE)--Trefoil Therapeutics today announced positive Phase 2 results for TTHX1114 in patients with Fuchs Endothelial Corneal Dystrophy.